Needham & Co. Senior Research Analyst Mike Matson today downgraded his rating of Medtronic (NYSE:MDT) and Zimmer Biomet (NYSE:ZBH) shares to Hold, while Boston Scientific (NYSE:BSX) got an upgrade to Buy. MDT shares were down more than 1% to $97.98 apiece in morning trading, a day after Q4 earnings that missed The Street sent the […]
Truist Securities
Stryker sees pandemic sales effects softening
Stryker (NYSE:SYK) executives see hip and knee procedures growing in 2021, based on a trend that started in March and continued in April. Such elective procedures were still sluggish in early 2021 due to the pandemic. Still, regional recovery from COVID-19 — particularly in the U.S. and Asia — bodes well for the company, CEO […]
Depleted hospital capital accounts are requiring medtechs to be `flexible’
As hospitals brace for another surge in COVID-19, medical device companies have to worry about more than temporary reductions in elective surgeries. Hospitals struggling to account for every dollar are beginning to push for new ways to select and pay for new medical technology, particularly large capital items like robotic surgery systems, according to […]
DTW Podcast: Who will win medtech’s own Supreme Court fight; and can the many mini Medtronics plan work?
In this week’s DeviceTalks Weekly podcast, we’ll first delve into Medtech’s own brewing Supreme Court battle. J. Michael Jakes, a partner at Finnegan, will tell us why the industry should be watching when the Supremes review the latest patent battle between Arthrex and Smith+Nephew. We’ll also talk about Medtronic’s Analyst Meeting where CEO Geoff Martha […]
DTW Podcast: Truist’s Kaila Krum says Medtronic prepping for growth
In an interview with DeviceTalks Weekly Podcast, Truist Securities managing director Kaila Krum says Medtronic executives are retooling the company to keep pace with smaller, more focused competitors. Breaking down the company’s Q1 call, Krum says Medtronic is seen as a company that’s too big to grow market share quickly. On the call, new CEO […]
